WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
Guangzhou Tinci Materials Technology (002709.SZ) plans to stop production and maintenance of its Longshan North Base annual production of 150,000 tons of liquid lithium hexafluorophosphate production line.
Guangzhou Tinci Materials Technology (002709.SZ) plans to adjust the production capacity of the expanded project of the electrolyte to 250,000 tons.
YUEXIU PROPERTY (00123) plans to sell 73.74% of the actual equity of Hangzhou Yueyunhe.
Guangzhou Tinci Materials Technology (002709.SZ) plans to stop production and maintenance of its Longshan North Base annual production of 150,000 tons of liquid lithium hexafluorophosphate production line.
Guangzhou Tinci Materials Technology (002709.SZ) plans to adjust the production capacity of the expanded project of the electrolyte to 250,000 tons.
YUEXIU PROPERTY (00123) plans to sell 73.74% of the actual equity of Hangzhou Yueyunhe.
RECOMMEND
Hong Kong Listed Companies’ Return To A Shares Heats Up As New “H To Shenzhen A” Case Emerges
05/01/2026
What Do The Top Ten Biopharma IPOs Of 2025 Tell Us?
05/01/2026
Asia’s Stock Markets Deliver A Strong 2025: Korea Soars 76%, Japan Tops Bubble‑Era Peak, Indonesia Records Best Year In 11 Years
05/01/2026
